Nimotuzumab in Pediatric Glioma

• Rickert CH , PaulusW: Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification.Childs Nerv. Syst.17(9), 503–511 (2001).
   PubMed Web of Science ®Google Scholar
• Finlay JL , BoyettJM, YatesAJet al.: Randomized Phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens cancer group.J. Clin. Oncol.13(1), 112–123 (1995).
   PubMed Web of Science ®Google Scholar
• Macdonald TJ , ArensonEB, AterJet al.: Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma: final analysis of children’s cancer group study 9933.Cancer104(12), 2862–2871 (2005).
   PubMed Web of Science ®Google Scholar
• Campbell JW , PollackIF, MartinezAJ, ShultzB: High-grade astrocytomas in children: Radiologically complete resection is associated with an excellent long-term prognosis.Neurosurgery38(2), 258–264 (1996).
   PubMed Web of Science ®Google Scholar
• Pollack IF , BoyettJM, YatesAJet al.: The influence of central review on outcome associations in childhood malignant gliomas: results from the ccg-945 experience.Neuro Oncol.5(3), 197–207 (2003).
   PubMed Web of Science ®Google Scholar
• Heideman RL , KutteschJJr, GajjarAJet al.: Supratentorial malignant gliomas in childhood: a single institution perspective.Cancer80(3), 497–504 (1997).
   PubMed Web of Science ®Google Scholar
• Sposto R , ErtelIJ, JenkinRDet al.: The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the childrens cancer study group.J. Neurooncol.7(2), 165–177 (1989).
   PubMed Web of Science ®Google Scholar
• Fouladi M , HuntDL, PollackIFet al.: Outcome of children with centrally reviewed low-grade gliomas treated with chemotherapy with or without radiotherapy on children’s cancer group high-grade glioma study ccg-945.Cancer98(6), 1243–1252 (2003).
   PubMed Web of Science ®Google Scholar
• Hegi ME , DiserensAC, GorliaTet al.: Mgmt gene silencing and benefit from temozolomide in glioblastoma.N. Engl. J. Med.352(10), 997–1003 (2005).
   PubMed Web of Science ®Google Scholar
• Stupp R , MasonWP, Van Den BentMJet al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.N. Engl. J. Med.352(10), 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Stupp R , Van Den BentMJ, HegiME: Optimal role of temozolomide in the treatment of malignant gliomas.Curr. Neurol. Neurosci. Rep.5(3), 198–206 (2005).
   PubMedGoogle Scholar
• Nicholson HS , KretschmarCS, KrailoMet al.: Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the children’s oncology group.Cancer110(7), 1542–1550 (2007).
   PubMed Web of Science ®Google Scholar
• Barone G , MauriziP, TamburriniG, RiccardiR: Role of temozolomide in pediatric brain tumors.Childs Nerv. Syst.22(7), 652–661 (2006).
   PubMed Web of Science ®Google Scholar
• Smith MA , FreidlinB, RiesLA, SimonR: Trends in reported incidence of primary malignant brain tumors in children in the United States.J. Natl Cancer Inst.90(17), 1269–1277 (1998).
   PubMedGoogle Scholar
• Hargrave D , BartelsU, BouffetE: Diffuse brainstem glioma in children: critical review of clinical trials.Lancet Oncol.7(3), 241–248 (2006).
   PubMed Web of Science ®Google Scholar
• Bouffet E , RaquinM, DozFet al.: Radiotherapy followed by high dose busulfan and thiotepa: a prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas.Cancer88(3), 685–692 (2000).
   PubMed Web of Science ®Google Scholar
• Mandell LR , KadotaR, FreemanCet al.: There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: Results of a pediatric oncology group Phase III trial comparing conventional vs hyperfractionated radiotherapy.Int. J. Radiat. Oncol. Biol. Phys.43(5), 959–964 (1999).
   PubMed Web of Science ®Google Scholar
• Packer RJ , BoyettJM, ZimmermanRAet al.: Outcome of children with brain stem gliomas after treatment with 7800 cgy of hyperfractionated radiotherapy. A childrens cancer group Phase I/II trial.Cancer74(6), 1827–1834 (1994).
   PubMed Web of Science ®Google Scholar
• Korones DN , FisherPG, KretschmarCet al.: Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral vp-16: a children’s oncology group Phase II study.Pediatr. Blood Cancer50(2), 227–230 (2008).
   PubMed Web of Science ®Google Scholar
• Albright AL : Tumors of the pons.Neurosurg. Clin. N. Am.4(3), 529–536 (1993).
   PubMedGoogle Scholar
• Barkovich AJ , KrischerJ, KunLEet al.: Brain stem gliomas: a classification system based on magnetic resonance imaging.Pediatr. Neurosurg.16(2), 73–83 (1990).
   PubMed Web of Science ®Google Scholar
• Donaldson SS , LaninghamF, FisherPG: Advances toward an understanding of brainstem gliomas.J. Clin. Oncol.24(8), 1266–1272 (2006).
   PubMed Web of Science ®Google Scholar
• Fischbein NJ , PradosMD, WaraW, RussoC, EdwardsMS, BarkovichAJ: Radiologic classification of brain stem tumors: correlation of magnetic resonance imaging appearance with clinical outcome.Pediatr. Neurosurg.24(1), 9–23 (1996).
   PubMed Web of Science ®Google Scholar
• Baselga J : Why the epidermal growth factor receptor? The rationale for cancer therapy.Oncologist7(Suppl. 4), 2–8 (2002).
   PubMed Web of Science ®Google Scholar
• Rivera F , Vega-VillegasME, Lopez-BreaMF, MarquezR: Current situation of panitumumab, matuzumab, nimotuzumab and zalutumumab.Acta Oncol.47(1), 9–19 (2008).
   PubMed Web of Science ®Google Scholar
• Gilbertson RJ , HillDA, HernanRet al.: Erbb1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma.Clin. Cancer Res.9(10 Pt 1), 3620–3624 (2003).
   PubMed Web of Science ®Google Scholar
• Brandes AA , FranceschiE, TosoniA, HegiME, StuppR: Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments.Clin. Cancer Res.14(4), 957–960 (2008).
   PubMed Web of Science ®Google Scholar
• Heimberger AB , HlatkyR, SukiDet al.: Prognostic effect of epidermal growth factor receptor and EGFRVIII in glioblastoma multiforme patients.Clin. Cancer Res.11(4), 1462–1466 (2005).
   PubMed Web of Science ®Google Scholar
• Liang ML , MaJ, HoMet al.: Tyrosine kinase expression in pediatric high grade astrocytoma.J. Neurooncol.87(3), 247–253 (2008).
   PubMed Web of Science ®Google Scholar
• Pelloski CE , BallmanKV, FurthAFet al.: Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma.J. Clin. Oncol.25(16), 2288–2294 (2007).
   PubMed Web of Science ®Google Scholar
• Preusser M , GelpiE, RottenfusserAet al.: Epithelial growth factor receptor inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study.J. Neurooncol.89(2), 211–218 (2008).
   PubMed Web of Science ®Google Scholar
• Omuro AM , FaivreS, RaymondE: Lessons learned in the development of targeted therapy for malignant gliomas.Mol. Cancer Ther.6(7), 1909–1919 (2007).
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK , WangMY, VivancoIet al.: Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.N. Engl. J. Med.353(19), 2012–2024 (2005).
   PubMed Web of Science ®Google Scholar
• Rich JN , ReardonDA, PeeryTet al.: Phase II trial of gefitinib in recurrent glioblastoma.J. Clin. Oncol.22(1), 133–142 (2004).
   PubMed Web of Science ®Google Scholar
• Franceschi E , CavalloG, LonardiSet al.: Gefitinib in patients with progressive high-grade gliomas: a multicentre Phase II study by gruppo italiano cooperativo di neuro-oncologia (gicno).Br. J. Cancer96(7), 1047–1051 (2007).
   PubMed Web of Science ®Google Scholar
• Van Den Bent MJ , BrandesAA, RamplingRet al.: Randomized Phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: eortc brain tumor group study 26034.J. Clin. Oncol.27(8), 1268–1274 (2009).
   PubMed Web of Science ®Google Scholar
• Haas-Kogan DA , PradosMD, TihanTet al.: Epidermal growth factor receptor, protein kinase b/akt, and glioma response to erlotinib.J. Natl Cancer Inst.97(12), 880–887 (2005).
   PubMed Web of Science ®Google Scholar
• Marie Y , CarpentierAF, OmuroAMet al.: EGFR tyrosine kinase domain mutations in human gliomas.Neurology64(8), 1444–1445 (2005).
   PubMed Web of Science ®Google Scholar
• Lee JC , VivancoI, BeroukhimRet al.: Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.PLoS Med.3(12), E485 (2006).
   PubMed Web of Science ®Google Scholar
• Schmittling RJ , ArcherGE, MitchellDAet al.: Detection of humoral response in patients with glioblastoma receiving EGFRVIII-KLH vaccines.J. Immunol. Methods339(1), 74–81 (2008).
   PubMed Web of Science ®Google Scholar
• Sampson JH , ArcherGE, MitchellDA, HeimbergerAB, BignerDD: Tumor-specific immunotherapy targeting the EGFRVIII mutation in patients with malignant glioma.Semin. Immunol.20(5), 267–275 (2008).
   PubMed Web of Science ®Google Scholar
• Bredel M , PollackIF, HamiltonRL, JamesCD: Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood.Clin. Cancer Res.5(7), 1786–1792 (1999).
   PubMed Web of Science ®Google Scholar
• Pollack IF , HamiltonRL, JamesCDet al.: Rarity of pten deletions and EGFR amplification in malignant gliomas of childhood: results from the children’s cancer group 945 cohort.J. Neurosurg.105(5 Suppl.), 418–424 (2006).
   PubMed Web of Science ®Google Scholar
• Thorarinsdottir HK , SantiM, MccarterRet al.: Protein expression of platelet-derived growth factor receptor correlates with malignant histology and pten with survival in childhood gliomas.Clin. Cancer Res.14(11), 3386–3394 (2008).
   PubMed Web of Science ®Google Scholar
• Khatua S , PetersonKM, BrownKMet al.: Overexpression of the EGFR/fkbp12/hif-2a pathway identified in childhood astrocytomas by angiogenesis gene profiling.Cancer Res.63(8), 1865–1870 (2003).
   PubMed Web of Science ®Google Scholar
• Harari PM , AllenGW, BonnerJA: Biology of interactions: antiepidermal growth factor receptor agents.J. Clin. Oncol.25(26), 4057–4065 (2007).
   PubMed Web of Science ®Google Scholar
• Crombet T , OsorioM, CruzTet al.: Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients.J. Clin. Oncol.22(9), 1646–1654 (2004).
   PubMed Web of Science ®Google Scholar
• Emrich JG , BradyLW, QuangTSet al.: Radioiodinated (i-125) monoclonal antibody 425 in the treatment of high grade glioma patients: ten-year synopsis of a novel treatment.Am J. Clin. Oncol.25(6), 541–546 (2002).
   PubMed Web of Science ®Google Scholar
• Broniscer A , BakerSJ, StewartCFet al.: Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma.Clin. Cancer Res.15(2), 701–707 (2009).
   PubMed Web of Science ®Google Scholar
• Geoerger B , HargraveD, NdiayeAet al.: ITCC Phase I study of erlotinib as single agent in children with refractory and relapsed malignant brain tumors and in combination with irradiation in newly diagnosed brain stem glioma.J. Clin. Oncol.25(18S) (2007) (Abstract 9556).
   PubMedGoogle Scholar
• Voelzke WR , PettyWJ, LesserGJ: Targeting the epidermal growth factor receptor in high-grade astrocytomas.Curr. Treat Options Oncol.9(1), 23–31 (2008).
   PubMed Web of Science ®Google Scholar
• Warren KE : Molecularly targeted therapy for pediatric brain tumors.J. Neurooncol. (75), 335–343 (2005).
   Google Scholar
• Pollack IF , JakackiRI, BlaneySMet al.: Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a pediatric brain tumor consortium report.Neuro Oncol.9(2), 145–160 (2007).
   PubMed Web of Science ®Google Scholar
• Benesch M , WindelbergM, SausengWet al.: Compassionate use of bevacizumab (avastin) in children and young adults with refractory or recurrent solid tumors.Ann. Oncol.19(4), 807–813 (2008).
   PubMed Web of Science ®Google Scholar
• Reuter CW , MorganMA, EckardtA: Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck.Br. J. Cancer96(3), 408–416 (2007).
   PubMed Web of Science ®Google Scholar
• Mateo C , MorenoE, AmourK, LombarderoJ, HarrisW, PerezR: Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity.Immunotechnology3(1), 71–81 (1997).
   PubMedGoogle Scholar
• Crombet T , TorresL, NeningerEet al.: Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer.J. Immunother.26(2), 139–148 (2003).
   PubMed Web of Science ®Google Scholar
• Morales AA , DucongeJ, Alvarez-RuizDet al.: Humanized versus murine anti-human epidermal growth factor receptor monoclonal antibodies for immunoscintigraphic studies.Nucl. Med. Biol.27(2), 199–206 (2000).
   PubMed Web of Science ®Google Scholar
• Sridhar SS , SeymourL, ShepherdFA: Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer.Lancet Oncol.4(7), 397–406 (2003).
   PubMed Web of Science ®Google Scholar
• Akashi Y , OkamotoI, IwasaTet al.: Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status.Br. J. Cancer98(4), 749–755 (2008).
   PubMed Web of Science ®Google Scholar
• Crombet-Ramos T , RakJ, PerezR, Viloria-PetitA: Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: a humanized anti-EGFR antibody.Int. J. Cancer101(6), 567–575 (2002).
   PubMed Web of Science ®Google Scholar
• Cedeno-Arias M , RengifoCE, BatistaYR, CalzadoER, RodriguezT: Immunohistochemical evaluation of h-R3 a novel humanized monoclonal antibody that neutralizes the EGF-receptor.Appl. Immunohistochem. Mol. Morphol.15(2), 213–219 (2007).
   PubMedGoogle Scholar
• Maceira M , RengifoE, CedenoM, MerinoN, Casaco ParadaA: Immunohistochemical recognition of the epidermal growth factor receptor by the h-R3 antibody in the skin of experimental animals.Appl. Immunohistochem. Mol. Morphol.12(4), 360–363 (2004).
   PubMedGoogle Scholar
• Torres LA , CocaMA, BatistaJFet al.: Biodistribution and internal dosimetry of the 188re-labelled humanized monoclonal antibody anti-epidermal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas.Nucl. Med. Commun.29(1), 66–75 (2008).
   PubMed Web of Science ®Google Scholar
• Torres LA , PereraA, BatistaJFet al.: Phase I/II clinical trial of the humanized anti-EGF-R monoclonal antibody h-R3 labelled with 99mtc in patients with tumor of epithelial origin.Nucl. Med. Commun.26(12), 1049–1057 (2005).
   PubMed Web of Science ®Google Scholar
• Crombet T , TorresO, NeningerEet al.: Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor.Cancer Biother. Radiopharm.16(1), 93–102 (2001).
   PubMed Web of Science ®Google Scholar
• Crombet T , TorresO, RodriguezVet al.: Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study.Hybridoma20(2), 131–136 (2001).
   PubMedGoogle Scholar
• Ramos TC , FigueredoJ, CatalaMet al.: Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial.Cancer Biol. Ther.5(4), 375–379 (2006).
   PubMed Web of Science ®Google Scholar
• Bode U , BuchenS, Warmuth-MetzM, PietschT, BachF, FleischhackG: Final report of a Phase II trial of nimotuzumab in the treatment of refractory and relapsed high-grade gliomas in children and adolescents.J. Clin. Oncol.25(Suppl. 18), 2006 (2007).
   PubMed Web of Science ®Google Scholar
• Bode U , WindelbergM, MassiminoMet al.: Phase III trial of nimotuzumab for the treatment of newly diagnosed diffuse intrinsic pontine gliomas in children and adolescents.J. Clin. Oncol.26(Suppl. 15), 2058 (2008).
   PubMed Web of Science ®Google Scholar
• Brade AM , MagalhaesJ, SiuLet al.: A single agent, Phase I pharmacodynamic study of nimotuzumab (theracim-h-R3) in patients with advanced refractory solid tumors.J. Clin. Oncol.25(Suppl. 18), 14030 (2007).
   Web of Science ®Google Scholar
• Pendharkar D , GuptaS, PalMK, HakimS, RashidT: Feasibility of combining humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 (nimotuzumab) with chemotherapy – a study of toxicity profile and tolerance.J. Clin. Oncol.25(Suppl. 18), 14030 (2007).
   Web of Science ®Google Scholar
• Allan DG : Nimotuzumab: Evidence of clinical benefit without rash.Oncologist10(9), 760–761 (2005).
   PubMed Web of Science ®Google Scholar
• Trippett TM , KutteschJ, HerzogCet al.: A Phase I study of cetuximab and irinotecan in pediatric patients (pts) with refractory solid tumors.J. Clin. Oncol.25(Suppl. 18), 9547 (2007).
   Web of Science ®Google Scholar
• Jakacki RI , HamiltonM, GilbertsonRJet al.: Pediatric Phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a children’s oncology group Phase I consortium study.J. Clin. Oncol.26(30), 4921–4927 (2008).
   PubMed Web of Science ®Google Scholar
• Daw NC , FurmanWL, StewartCFet al.: Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a children’s oncology group study.J. Clin. Oncol.23(25), 6172–6180 (2005).
   PubMed Web of Science ®Google Scholar
• Fouladi M , NicholsonHS, ZhouTet al.: A Phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a children’s oncology group study.Cancer110(11), 2535–2541 (2007).
   PubMed Web of Science ®Google Scholar
• Haas-Kogan DA , BanerjeeA, KocakMet al.: Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma.Neuro Oncol.10(3), 341–347 (2008).
   PubMed Web of Science ®Google Scholar
• Casaco A , LopezG, GarciaIet al.: Phase I single-dose study of intracavitary-administered nimotuzumab labeled with 188 re in adult recurrent high-grade glioma.Cancer Biol. Ther.7(3), 333–339 (2008).
   PubMed Web of Science ®Google Scholar

Websites

• National Cancer Institute website www.cancer.gov (Accessed May 16, 2009)
   Google Scholar
• OncoScience website: a co-operation founded with the goal to fill gaps in the treatment of rare diseases and marketing of nimotuzumab www.oncoscience-ag.de/en/news.htm (Accessed May 16, 2009)
   Google Scholar
• YM Biosciences Inc. (developers of nimotuzumab) press release: YM Biosciences USA enrolls first patient in Phase II trial of nimotuzumab in children with inoperable, recurrent brain cancer www.ymbiosciences.com/investors/press_releases_item.php?newsid=1202345 (Accessed May 16, 2009)
   Google Scholar
• YM Biosciences Inc. website: information on nimotuzumab www.ymbiosciences.com/products/nimotuzumab/index.php (Accessed May 16, 2009)
   Google Scholar
• ClinicalTrials.gov website: Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas http://clinicaltrials.gov/ct2/show/NCT00042991 (Accessed October 22, 2009)
   Google Scholar
• ClinicalTrials.gov website: Lapatinib in Treating Young Patients With Recurrent or Refractory CNS Tumors http://clinicaltrials.gov/ct2/show/NCT00095940 (Accessed October 22, 2009)
   Google Scholar